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Abstract
In Germany, ~8 million patients take angiotensin receptor blockers (ARBs) and 2.25 million of them valsartan. In 2018,
contamination of generic ARBs with probable carcinogenic nitrosamines resulted in more than 30 recalls. The impact of
such a huge recall has never been explored in Europe. We analyzed the utilization of valsartan, all ARBs, and other
alternative antihypertensive drugs in Germany. We used our database of anonymized dispensing data from >80% of
community pharmacies at the expense of the statutory health insurance (SHI) funds from January 2017 to December
2019. We analyzed 290.8 million prescriptions, including all oral mono- and fixed-dose combinations of ARBs and
plausible alternatives, i.e. ACE inhibitors (ACEi), beta-blockers (BB), and calcium channel blockers (CCB). Utilization
was calculated by defined daily doses per 1000 SHI-insured persons per day (DID). Valsartan use decreased
substantially after the recalls in July 2018 from 39.0 to 14.2 DID (−64%) in the second quarter of 2019 and to 16.9 DID
(−57%) in the fourth quarter of 2019. Simultaneously, the use of alternative ARBs increased from 77.7 DID in the
second quarter of 2018 to 121.9 DID (+57%) in the fourth quarter of 2019, mainly due to an increase of candesartan
dispensing to 99.8 DID (+73%). There were no changes in the utilization of ACEi, BB, or CCB. The majority of
recalled generic valsartan products were replaced by other ARBs, predominantly candesartan, despite documented drug
shortages. In contrast to previous safety warnings/recalls, our data do not suggest an under-prescription of
antihypertensives during this period.
Introduction
Angiotensin receptor blockers (ARBs) are the most com-
monly used drugs for the treatment of arterial hypertension,
heart failure, and chronic kidney disease [1]. In Germany,
~8 million patients take ARBs and 2.25 million of them
valsartan [2].
In accordance with the European Medicines Agency, the
German Federal Institute for Drugs and Medical Devices
announced recalls of generic valsartan products on July 4th,
2018 [3]. The drugs were recalled due to high concentrations
of probable carcinogenic nitrosamines found in selected lots of
ARB substances and generic drugs, primarily valsartan from
Zhejiang Huahai Pharmaceutical Co., Ltd., Linhai, China.
These impurities were most likely related to a change in the
manufacturing process of the valsartan substance implemented
in 2012 [4]. Subsequently, 16 marketing authorization holders
recalled affected batches of more than 30 generic drugs con-
taining impurities. Drug products from the originator and a
couple of generic products utilizing valsartan from other
production facilities were not recalled. Later recalls from
August 2018 to March 2019 involved further generic valsartan
products as well as generic irbesartan and losartan [5, 6].
Other manufacturers and other drug classes were recognized
to be contaminated with nitrosamines and were recalled
worldwide [5]. Previous safety warnings and medication
recalls were associated with gaps in prescriptions and often
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associated with adverse health outcomes, also due to drug
shortages [7–10].
To the best of our knowledge, the impact of this
huge drug product recall on the further use of anti-
hypertensive medication has never been explored in Europe.
We, therefore, analyzed the utilization of valsartan, all
ARBs, and other alternative antihypertensive drugs, that
are angiotensin-converting enzyme inhibitors (ACEi), beta-
blockers (BB), and calcium channel blockers (CCB) before
and after the recalls in Germany.
Methods
This drug utilization study used the database of the German
Institute for Drug Use Evaluation (DAPI) containing
anonymous dispensing data of community pharmacies [11].
Data from a representative sample of more than 80% (until
06/2019) and more than 95% (from 07/2019 onwards) of
German community pharmacies were available. The data
were extrapolated by regional factors to 100% of the
population insured by the statutory health insurance (SHI)
covering 88% of Germany’s population. Until 06/2019
regional factors were calculated by dividing the number of
community pharmacies by the number of pharmacies cov-
ered by the DAPI database in the respective region. From
07/2019 onwards, regional factors were calculated by
dividing the number of dispensed packages reported by a
federal information system about SHI-covered prescriptions
known as GAmSi (GKV-Arzneimittel-Schnellinformation)
[12] by dispensed packages in the DAPI database in the
respective region. Prescriptions for privately insured
patients are not covered by our database. Data on the
indication, treatment duration, or dosages as well as data on
individual patients were not available.
Using the specific product code (Pharmazentralnummer,
an identification number for pharmaceutical products in
Germany), dispensing data were linked to a database con-
taining information on the brand/generic name, composi-
tion, active ingredients, package size, dosage form, and
route of administration [13].
The dispensings of antihypertensives in Germany in the
period from January 2017 to December 2019 were explored
to illustrate the changes in utilization after the recalls in the
second half of 2018. Apart from ARBs, we analyzed ACEi,
BB, and CCB as plausible alternatives as well as for com-
parison of dispensing data. Hence, all orally administered
mono- and fixed-dose combinations containing the follow-
ing drug classes were included: ARB, ACEi, BB, and CCB.
The allocation of the active ingredients was based on the
official version of the Anatomical Therapeutic Chemical
(ATC) classification system with defined daily doses (DDD)
published by the German Institute of Medical Documentation
and Information [14]. DDD are the assumed average daily
maintenance dose for the main indication of a drug in adults
[15]. Individual substances were analyzed according to the
ATC code level 5. For the analysis of individual ARBs, we
included mono preparations and combinations with hydro-
chlorothiazide only because those were affected by the recalls.
In Germany, antihypertensive drugs are usually dispensed
in a 3-months’ supply, that is in general 100 tablets in a norm
size N3 drug package. It is possible to prescribe more than
one drug package per prescription.
As the drug utilization unit, the DDD per 1000 inhabitants
per day (DID) was used providing an estimate of the propor-
tion of the population treated daily with a particular drug or
group of drugs [15]. The DID is a global, technical unit used
for evaluation of drug utilizations and treatment frequencies
allowing comparisons across various time periods [16]. Com-
pared to other measurement parameters, DID has the advantage
that drug utilization is measured using a standardized amount
of active ingredient. To adapt for the SHI-insured population
analyzed, we calculated the DDD per 1000 SHI-insured per-
sons per day. The numbers of SHI-insured persons were
obtained from the Federal Ministry of Health [17].
We calculated moving averages per month regarding the
respective month and the two previous months to smooth
short-term fluctuations and highlight longer-term trends.
For the individual ARBs, we also observed the dispensed
DID on a daily basis. To determine differences in the dis-
pensing of 2018 compared with 2017 we divided the DID of
the weekdays in June and July 2018, the month of first
recalls, by the weekdays in June and July 2017. We
excluded Sundays for better comparability.
DID ratio of matchedweekdays ¼ DID 2018ð Þof weekday x
DID 2017ð Þof weekday x
:
To control for drug expenditures, health insurance funds
are closing so-called rebate contracts with, above all, the
generic pharmaceutical industry. These contracts require the
pharmacist to dispense a specific generic drug product.
The inability to fulfill rebate contracts of the SHI in the
pharmacy due to unavailability of rebated drugs and the
subsequent dispensing of a drug not rebated is documented
by printing a specific code on the prescription [18]. The
amount of prescriptions with this code was taken as an
indicator for potential drug shortages.
Results
The analyses included 290.8 million prescriptions for anti-
hypertensive drugs from January 2017 to December 2019
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(Table 1). 47% of all included product codes of anti-
hypertensive drugs were fixed-dosed combinations with
17% of total dispensings. Of these, 67% were combination
products with hydrochlorothiazide with 80% of the dis-
pensings of all combination products, and 49% were com-
binations containing ARBs and hydrochlorothiazide with
40% of the dispensings of all combination products.
The dispensings of valsartan products remained at a
constant average level of 39.0 DID from January 2017 until
June 2018 (Table 2, Figs. 1 and 2). After the first recalls of
valsartan products in July 2018, dispensings decreased
substantially and continuously to an average of 27.2 DID
(−30%) in the first quarter (Q1) of 2019 and subsequently
to 14.2 DID (−64%) in Q2 2019. Throughout the second
half of 2019, valsartan dispensings remained low with 15.2
DID (−61%) in Q3 2019 and 16.9 DID (−57%) in Q4 2019
(Table 2; Fig. 1).
The market shares for generic valsartan products recalled
in July and November 2018 were both 45% in the 3-month
period prior to the respective recall. Before the first recall,
non-recalled and recalled valsartan products together had a
market share of 35% of all ARBs, which decreased to 26%
(−26%) in the second half of 2018 and to 12% (−66%) in
the second half of 2019.
With the decrease of valsartan, alternative ARBs increased
by an average of 7.4 DID per quarter (from 77.7 DID in Q2
2018 to 121.9 DID (+57%) in Q4 2019). Candesartan was
the ARB with the largest increase in prescription (average
increase of 7.0 DID per quarter from 57.7 DID in Q2 2018
to 99.8 DID (+73%) in Q4 2019 (Fig. 1 and Table 2)).
For telmisartan, losartan, and olmesartan, only a slight
increase of dispensing was observed (Table 2).
Before the first recalls in July 2018, the ratio of the
matched daily dispensings for valsartan and candesartan
predominantly showed values close to 1, with the exception
of public holidays. After the first recalls were instituted, the
ratio initially increased to 1.43 for valsartan and 1.30 for
candesartan, respectively. Afterwards, the ratio decreased
substantially to 0.65 for valsartan while the values for
candesartan reached 1.56–1.27 (Fig. 2).
For valsartan and candesartan mono and hydro-
chlorothiazide combinations, a substantial increase in the
amount of prescriptions with documented unavailability of
rebated drugs could be observed from July 2018 onwards
(Fig. 3). For valsartan, the amount of documented una-
vailability increased from 2200 prescriptions in June 2018
to a peak of 242,400 prescriptions in January 2019 and
subsequently decreased to 4900 in December 2019. For
candesartan, the number increased steadily from 1400 in
June 2018 to 406,100 in November 2019. In 2019, in total
2.2 million out of 14.9 million (15%) dispensing processes
of candesartan drug products were unavailable. For valsar-
tan, in about 1.0 million out of 3.5 million (29%) dispen-
sings, drug products were unavailable.
There was no impact of the recalls on the moderate, but
continuous increase of the total dispensing of all ARBs.
Utilization of ACEi, BB, and CCB remained nearly
unchanged (Fig. 4).
Discussion
The more than 30 recalls of generic drug products containing
ARBs from July 2018 to March 2019 due to impurities with
probable carcinogenic nitrosamines led to a rapid and sub-
stantial decrease in valsartan and a compensatory increase in
candesartan dispensings, resulting in an increase in the total
volume of ARB prescriptions from 2018 to 2019. Dispen-
sings of ACEi, BB, and CCB remained nearly unchanged.
The data, therefore, suggest that patients were primarily
switched within the class of ARBs, mostly from valsartan to
candesartan. Interestingly, and in contrast to other medication
safety warnings/recalls and subsequent drug shortages, the
data do not suggest an under-treatment on a population level
during this period [7–10, 19].
Valsartan is a guideline-recommended drug for the treat-
ment of hypertension and heart failure and is administered in
cumulative daily doses of 80–320mg [20, 21]. Valsartan was
patent-registered in 1991 and became generic in 2011. The
market share of generic valsartan before the recalls was 35%
of all ARB in Germany. Prior to the generic valsartan recalls,
candesartan was already the most frequently prescribed ARB
with 57.7 DID, followed by valsartan with 39.0 DID.
Table 1 Number of prescriptions for antihypertensive drugs, dispensed
drug packages, and drug packages per prescription 2017–2019.
Year and
quarter
AHT prescriptions
(million)
Drug
packages
(million)
Drug packages
per prescription
2017 Q1 23.6 28.9 1.22
2017 Q2 23.9 29.4 1.24
2017 Q3 23.6 29.0 1.23
2017 Q4 24.4 30.0 1.23
2018 Q1 23.9 29.4 1.23
2018 Q2 24.4 30.0 1.23
2018 Q3 23.9 29.2 1.22
2018 Q4 24.6 30.2 1.23
2019 Q1 24.0 29.4 1.22
2019 Q2 24.7 30.3 1.22
2019 Q3 24.5 30.1 1.23
2019 Q4 25.2 31.0 1.22
Total 290.8 356.8 1.23
Average per
quarter
24.2 million 29.7 million 1.227
AHT antihypertensive drugs, Q quarter.
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In contrast, in the US, where losartan is traditionally the most
frequently used ARB, recalled generic valsartan was primarily
replaced by losartan [22, 23]. Differences in the preferred
active pharmaceutical ingredient are possibly influenced by
the pharmaceutical company that had initially provided the
brand marks in the 1990th or due to drug prices [24].
Our analyses suggests that only a minority of patients
received new prescriptions for other ARBs than cande-
sartan, such as losartan, telmisartan, irbesartan, olmesartan,
azilsartan, or eprosartan. Similarly, the utilization of plau-
sible alternative drugs remained unchanged suggesting that
patients treated with valsartan were switched to another
ARB. A change from valsartan to candesartan has the
advantage of an easy estimation of the equivalent dose of
candesartan (8–32 mg per day) which is roughly one-tenth
of the valsartan dose. Physicians seem to prefer a change to
an ARB with which they have the most experiences and/or
which is broadly available on the market. Within-class
Table 2 Monthly dispensings of angiotensin receptor blockers in DID from January 2017 to December 2019.
DID
Month Valsartan Candesartan Losartan Telmisartan Irbesartan Olmesartan Eprosartan Azilsartan All ARBs
Jan 2017 36.9 50.5 7.7 6.3 4.8 0.4 0.4 0.02 106.9
Feb 2017 36.7 50.4 7.7 6.3 4.7 0.4 0.4 0.01 106.6
Mar 2017 38.6 53.2 7.9 6.6 4.9 0.5 0.4 0.02 112.0
Apr 2017 37.2 51.3 7.6 6.4 4.8 0.5 0.4 0.02 108.2
May 2017 39.1 54.1 7.9 6.6 4.9 0.6 0.4 0.02 113.7
June 2017 38.3 52.6 7.7 6.4 4.8 0.6 0.3 0.02 110.8
July 2017 38.5 53.2 7.7 6.4 4.8 0.7 0.3 0.01 111.6
Aug 2017 37.0 51.0 7.4 6.2 4.5 0.7 0.3 0.01 107.1
Sep 2017 37.5 51.7 7.4 6.2 4.5 0.7 0.3 0.01 108.2
Oct 2017 38.1 52.9 7.5 6.3 4.6 0.8 0.3 0.01 110.4
Nov 2017 43.4 60.1 8.4 7.0 5.1 0.9 0.3 0.02 125.3
Dec 2017 37.9 52.8 7.4 6.2 4.4 0.8 0.3 0.01 109.7
Jan 2018 40.8 56.6 7.9 6.4 4.6 0.9 0.3 0.01 117.5
Feb 2018 39.5 55.4 7.7 6.2 4.5 1.0 0.3 0.02 114.5
Mar 2018 39.3 55.4 7.6 6.2 4.5 1.0 0.3 0.01 114.1
Apr 2018 42.0 58.9 8.1 6.5 4.7 1.1 0.3 0.01 121.5
May 2018 40.1 56.2 7.7 6.1 4.4 1.0 0.3 0.01 115.8
June 2018 41.2 57.9 7.9 6.3 4.5 1.1 0.3 0.01 119.1
July 2018 41.8 69.6 8.5 6.8 4.8 1.4 0.3 0.01 133.3
Aug 2018 28.9 67.5 8.0 6.3 4.4 1.4 0.3 0.01 116.7
Sep 2018 27.4 62.0 7.5 5.9 4.1 1.3 0.3 0.01 108.4
Oct 2018 33.2 73.0 8.5 6.8 4.8 1.5 0.3 0.01 127.9
Nov 2018 30.8 76.7 8.8 7.0 4.8 1.6 0.3 0.01 130.0
Dec 2018 25.5 68.7 7.7 6.1 4.2 1.5 0.2 0.01 113.8
Jan 2019 32.8 79.4 8.6 6.9 4.8 1.7 0.3 0.01 134.4
Feb 2019 26.9 79.7 8.3 6.9 4.6 1.7 0.3 0.01 128.3
Mar 2019 22.1 74.3 7.6 6.3 4.2 1.6 0.2 0.01 116.5
Apr 2019 19.6 90.5 8.8 7.4 4.9 1.9 0.3 0.01 133.3
May 2019 10.0 101.6 8.9 7.6 4.9 2.1 0.2 0.01 135.3
June 2019 13.0 90.0 8.0 6.9 4.5 1.8 0.2 0.01 124.4
July 2019 17.6 99.2 9.1 7.7 5.0 1.9 0.3 0.01 140.8
Aug 2019 13.9 90.0 7.9 6.7 4.4 1.9 0.2 0.01 125.0
Sep 2019 13.9 91.3 7.9 6.8 4.4 1.9 0.2 0.01 126.4
Oct 2019 17.2 101.0 9.1 7.6 4.6 2.1 0.2 0.01 141.8
Nov 2019 18.1 104.4 9.0 7.8 2.9 2.2 0.2 0.01 144.6
Dec 2019 15.5 93.9 8.0 7.0 3.6 2.0 0.2 0.01 130.1
ARB angiotensin receptor blocker, DID defined daily doses per 1000 statutory health insurance-insured persons per day.
906 U. M. Rudolph et al.
Fig. 1 Utilization of
angiotensin-II receptor
blockers. Utilization of
angiotensin-II receptor blockers
in DID over time; only mono
preparations and fixed-dose
combinations with
hydrochlorothiazide where
included DID defined daily
doses per 1000 statutory health-
insured persons per day.
Fig. 2 Ratio of the matched
daily dispensings for valsartan
and candesartan. 2018–2017
ratios of matched weekdays in
June and July for dispensings of
valsartan and candesartan DID
defined daily doses per
1000 statutory health-insured
persons per day.
Fig. 3 Unavailability of
valsartan and candesartan
drug products. Number of
prescriptions with documented
unavailability for valsartan and
candesartan drug products over
time; only mono preparations
and fixed-dose combinations
with hydrochlorothiazide were
included.
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replacement of valsartan and the increase of ARB-
prescriptions in general seen in our study and the US sug-
gest that physicians are convinced of the efficacy and
tolerability of ARBs [21, 23–25].
After the first recall, utilization of valsartan did not
decrease by the recalled 45%, but by 28%. About 40% of
recalled valsartan might have been replaced by non-recalled
valsartan. The second recall, however, led to a reduction of
valsartan dispensing that exceeded the amount of the
recalled products by ~22%. The intensified decline after
several recalls and the reduction of valsartan market share
of all ARBs may reflect emerging issues of drug supply and
potential uncertainty with regard to additional recalls.
Recently, two studies investigated the consequences of
ARB recalls in North-America [19, 23]. Analyzing a data-
base in Ontario, Canada, covering 55,461 patients, 73.8% of
recalled valsartan users switched to non-valsartan ARBs
and 8.8% to a non-recalled valsartan product within one
month after the recall, but 10.7% of patients did not fill an
alternative medication at 3 month after the recall [19]. The
lack of replacement of recalled valsartan was associated
with increased healthcare utilization [19].
In a second study on 9 million generic ARB prescriptions
in the United States, 37% of total ARB use prior to recalls
was affected by recalls [23]. Generic valsartan use decreased
by 53 to 10% in March 2019. Use of losartan increased after
the first valsartan recalls from 67 to 73%, but decreased to
71% in March 2019 following recalls of losartan [23].
These as well as our data do not allow conclusions on
medication adherence or clinical outcomes. The observed
slight increase of prescriptions for antihypertensives in our
observation period makes it likely that the majority of
patients received new prescriptions. In Germany, the health
insurance companies covered the additional costs of
new prescriptions of recalled or exchanged nonavailable
rebated drugs.
The valsartan recalls led to unavailability of a large amount
of rebated valsartan products which was followed by una-
vailability of rebated candesartan products [26]. It appears that
these supply bottlenecks could be substituted by other generic
or non-rebated drugs at least within the same quarter. In 2019,
valsartan and candesartan were documented in Germany in
the group of the ten most active ingredients with unavail-
ability of rebated drugs [26]. As dispensed drug packages of
ARBs rose from 2017 to 2019, it might be assumed that this
did not result in a shortage of suitable ARBs in general.
However, evaluation of unavailable rebated drugs has several
pitfalls leading to an underestimation of the entirety of una-
vailable drugs [26]. For example, only those prescriptions can
be counted that have been converted in the pharmacy. Drug
shortages are a complex problem of growing concern and
represent a constant challenge for pharmacists in everyday
practice [8–10].
Two recent trends also affect utilization of cardiovascular
drugs: nearly ubiquitous reliance on generic drug products
and increased use of manufacturing facilities in China and
India [27]. The most common reason for product recalls is
manufacturing issues. An investigation of FDA drug recalls
lists contamination, mislabeling, adverse reaction, defective
product, and incorrect potency as common causes for recalls
[28]. Other causes include regulatory issues, discontinuation
of products from the market, procurement issues, business
decisions and natural disasters [7]. Recalls may trigger errors,
confusion and negatively impact medication adherence [29].
Recalls may also impair the relationship of the patient with
physicians, pharmacists, and the health care system [30]. Drug
recalls may result in change to an active ingredient of second
choice, lower dosages, inaccurate use of the alternative
medication, a delay or impossibility of a vitally important
therapy for patients, or discontinuation of treatment [7–10].
About 60% of pharmacists surveyed in Germany reported
impaired medication adherence due to drug shortages [29].
Fig. 4 Utilization of
antihypertensive drugs.
Utilization of antihypertensive
drugs in DID over time. ACEi
angiotensin-converting enzyme
inhibitors, ARB angiotensin-II
receptor blockers, BB beta
blockers, CCB calcium channel
blockers, DID defined daily
doses per 1000 statutory health-
insured persons per day.
908 U. M. Rudolph et al.
Impurities with nitrosamines, primarily hepatotoxic N-
nitrosodimethylamine (NDMA) and N-nitrosodiethylamine
(NDEA), may occur in the manufacturing of ARBs con-
taining a tetrazol-group (valsartan, candesartan, irbesartan,
losartan, and olmesartan) [22, 31]. On 31th January 2019,
the European Medicines Agency (EMA) recommended that
companies producing ARBs review their manufacturing
processes so that nitrosamine impurities do not develop
[31]. In humans, nitrosamines were graded by the World
Health Organization as probable human carcinogens due to
their potential to damage DNA. For the vast majority of
ARBs, nitrosamine impurities were either not found or were
present at very low levels. The extrapolation of the highest
possible cancer risk estimated 22 extra cases of cancer due
to NDMA over the lifetimes of 100,000 patients who took
valsartan from Zhejiang Huahai Pharmaceutical Co., Ltd.,
China—where the highest levels of impurities were
found—every day for 6 years at the highest dose, and eight
extra cases in 100,000 patients due to NDEA taking the
medicine at the highest dose every day for 4 years. The
estimates have been extrapolated from animal studies and
are very low compared with the lifetime risk of cancer in the
EU (1 in 2) [31]. Anyhow, exposed patients require long-
term monitoring [4].
In 2018, a second large AHT class was widely discussed
because of potential carcinogenic effects: Hydrochlorothiazide
was reported to be dose-dependently associated with
development of nonmelanoma skin cancer [32, 33]. Hydro-
chlorothiazide drug products were not recalled but according
to a safety warning via a Dear Healthcare Professional Letter,
patients had to be informed about the increased risk and the
need to control their skin regularly and to use sun protection
[34, 35]. This situation likely contributed to the absence of a
switch from valsartan to hydrochlorothiazide or thiazide-like
diuretics. It also aggravated the overall uncertainty with regard
to cardiovascular drug therapies. This is exemplified by the
increased reporting of neoplasms [36].
Our study has strengths and limitations. Limitations
include not having patient level information including
indications for treatment and potential impact on patient
outcomes. Some use of ARBs is certainly for indications
other than hypertension e.g., heart failure. However, the
observed increase of prescriptions of antihypertensive drugs
in the observation period makes it likely that most patients
received new prescriptions. The strength includes the very
large and reliable sample of >290 million prescriptions in
~88% of Germany’s entire population. While for most
valsartan drug products all batches were recalled, for some
generic products only certain batches were affected by a
recall. Due to the impossibility to differentiate between
batches in valsartan products, we considered all dispensings
of a product as recalled if one batch was affected by the
recall. This may have resulted in a small overestimation of
recalled generic valsartan but did not change the decrease of
overall valsartan use or its share of all ARBs.
Conclusions
The many recalls of ARBs, primarily generic valsartan drug
products from July 2018 to March 2019 due to impurities
with probable carcinogenic nitrosamines led to a rapid and
substantial decrease in prescriptions for valsartan. Recalled
valsartan products were mainly replaced by other ARBs,
predominantly candesartan. In addition, the total volume of
ARB prescriptions also increased, while utilization of
ACEi, BB, and CCB remained nearly unchanged.
Despite the temporal drug shortages of ARBs, our data
do not suggest an under-prescribing with antihypertensive
drugs during the follow-up period until the end of 2019.
Summary
What is known about topic
● In 2018, contamination of angiotensin receptor blockers
(ARB) with probable carcinogenic nitrosamines resulted
in more than 30 drug recalls.
● In the US, recalled valsartan was mainly replaced by
losartan.
● Previous safety warnings and medication recalls were
associated with gaps in prescriptions and often associated
with adverse health outcomes, also due to drug shortages.
● ARB recalls were associated with increased healthcare
utilization in Canada.
What this study adds
● In Germany, a within class replacement of recalled
valsartan products was also found, but mainly to
candesartan.
● The total volume of ARB prescriptions increased, while
utilization of angiotensin converting enzyme inhibitors,
betablockers, and calcium channel blockers remained
nearly unchanged.
● Despite temporal drug shortages of ARBs, our data do
not suggest an under-prescription with antihypertensive
drugs during the follow-up period.
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